From left: Massimo Scaccabarozzi, Roberto Speranza, Damiano Coletta
Published on: 15/10/2020 11:45
Johnson & Johnson has foreseen substantial investments by the end of 2021 for the establishment of its Janssen pharmaceutical division in Latina. These are resources that have made the Italian production site a flagship in the field of pharmacological innovation worldwide. “The investment in Latina is a testimony of the vocation for innovation that has always characterized Janssen, both from the point of view of production and medical research, as confirmed by the company’s commitment to the development of its candidate vaccine against Covid- 19 “, reads a note.
Born in the 1980s, the production site covers an area of 136 thousand square meters and its production, which today amounts to 4.5 billion innovative oral treatments every year, intended in particular for the treatment of onco-haematological diseases and to the treatment of infectious diseases, it will potentially reach 5 billion in 2021. More than 95% of this production is destined abroad, to reach patients in over 100 countries around the world.
The Latina plant has always been the protagonist of an important technological evolution in the name of environmental sustainability, thanks to which, in 2018, it was chosen as a partner site of the Janssen Research and Development Center and saw the activation of the first linea in continuum, a production system applied for the first time in Italy in the pharmaceutical field and based on the robotization of operations to allow the simplification of activities and better process control.
Despite the pandemic, Janssen has kept production intact within the plant, to ensure continuity of care for all patients. Furthermore, during the most acute phase of the emergency, the company has also continued its commitment to innovation, doubling the automated production line in continuum. The introduction of this second line allowed the site to make use of all three existing technologies for the production of solid treatments (wet granulation, dry granulation and direct compression), further strengthening the capacity of the Latina plant to produce any Janssen’s new oral treatment and to launch it globally.
The technological development of the plant also affects the people who make up the Janssen organization. In the last 4 years, the staff of Latina has more than doubled, going from 320 to 770 people, with a great growth in professional skills and a widespread orientation towards self-employment. These two elements have been the fertile ground for the launch of an initiative that allows all Janssen employees to present new valuable ideas, which can be funded and augmented, after evaluation by the executive committee. In 3 years, over 370 new proposals have been submitted and several have been improved, such as remote control of the production process via smartwatch.
“Janssen has always been committed to the research and development of new health solutions: innovation is the daily challenge of the more than 1,500 people who make up our organization”, said Massimo Scaccabarozzi, president and CEO of Janssen Italia. “In recent years, the Latina plant has been the protagonist of an important technological evolution with positive economic and social impacts for our whole country. Following the doubling of the ‘in continuum’ production system, the Janssen site will attract development of further innovative therapies in our country “.
REPRODUCTION RESERVED © Copyright Adnkronos.